Fibrin Sealant Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented by Product (Liquid Form, Patch), By End User (Ambulatory Surgical Centers, Hospitals, Specialty Clinics), By Region & Competition, 2020-2030F

Market Overview

Global Fibrin Sealant Market was valued at USD 1.32 Billion in 2024 and is expected to reach USD 1.86 Billion by 2030 with a CAGR of 6.09%. The fibrin sealant market has become an essential component of modern surgical procedures and wound management, playing a pivotal role in the evolving landscape of medical technology. Fibrin sealants, commonly referred to as fibrin glues, are hemostatic agents used to promote blood clotting and seal wounds during and after surgeries. With the global increase in surgical procedures, fueled by an aging population, rising cases of chronic diseases, and higher rates of trauma—the demand for fibrin sealants continues to grow. The key drivers of this market is the shift toward minimally invasive surgeries, which require tools that offer precision, rapid action, and effective wound closure. Fibrin sealants are highly valued in such procedures due to their ease of application, biocompatibility, and ability to significantly reduce post-operative complications. Surgeons rely on them not only in planned operations but also in emergency settings like trauma or accident cases, where quick wound sealing and bleeding control are critical.

However, despite their widespread clinical benefits, fibrin sealants face certain limitations. The high cost of quality sealants can be a barrier to adoption, especially in developing countries or healthcare systems with limited budgets. Since many sealants are derived from human plasma, there is a minimal yet notable risk of disease transmission, prompting concerns about long-term safety.

To overcome these challenges, research and development efforts are increasingly focused on synthetic and recombinant fibrin sealants that eliminate the risks associated with human-derived products. Advances in bioengineering are paving the way for innovative sealants that offer improved efficacy, enhanced safety, and faster healing times. These developments are also expanding the application scope of fibrin sealants beyond general surgery to include areas such as sports medicine, orthopedics, and cosmetic surgery. The fibrin sealant market stands at the intersection of technological innovation and critical patient care. As the industry continues to evolve, stakeholders, including manufacturers, healthcare providers, and regulatory bodies, must prioritize product innovation, affordability, and safety. With its expanding applications and growing clinical importance, the fibrin sealant market is poised for sustained growth and a deeper impact on global healthcare outcomes.

Key Market Drivers

Emerging Applications of Fibrin Sealant in Microsurgery and Implant Site Flap Closure is Major Factor for Fibrin Sealant Market Growth

The global fibrin sealant market is experiencing substantial growth, primarily driven by the emerging applications of fibrin sealant in microsurgery and implant site flap closure. Fibrin sealant, also known as tissue glue or surgical glue, is a biocompatible adhesive derived from human plasma proteins. It has been widely used in various surgical procedures for hemostasis and tissue sealing. Microsurgery is a highly specialized field that involves intricate procedures on very small structures, often using high-powered microscopes. Fibrin sealant has found emerging applications in microsurgery due to its ability to provide precise and controlled tissue adhesion.

In microsurgical applications, the use of fibrin sealant offers several advantages, including reduced operative time, minimal tissue trauma, and improved postoperative recovery. It allows surgeons to achieve hemostasis and close tissues with high precision. Fibrin sealant is increasingly utilized in implant dentistry for site flap closure during dental implant procedures. It plays a crucial role in securing flaps over implant sites, ensuring proper healing and osseointegration. The success of microsurgical and implant procedures heavily relies on the choice of adhesive. Surgeons demand reliable, biocompatible adhesives that can securely close tissues and promote effective healing without causing adverse reactions.

Fibrin sealant is known for its versatility. It can be used in various surgical specialties, including neurosurgery, ophthalmology, plastic surgery, and more, making it a valuable tool in the medical field. In microsurgery and implant site flap closure, precision and safety are paramount. Fibrin sealant provides the controlled and localized tissue adhesion required for successful outcomes while minimizing the risk of complications. Ongoing research and development efforts in the field of fibrin sealant have led to advanced formulations that offer improved adhesion strength, hemostatic properties, and biocompatibility. These advancements contribute to its growing adoption in microsurgery and implant dentistry. The increasing demand for precise and effective tissue adhesives in microsurgery and implant procedures is driving the need for specialized fibrin sealant products. Surgeons and healthcare professionals seek advanced solutions to enhance surgical outcomes.

The global fibrin sealant market is experiencing robust growth, primarily driven by the emerging applications of fibrin sealant in microsurgery and implant site flap closure. Fibrin sealant has become an essential tool in achieving secure tissue adhesion and promoting healing in delicate surgical procedures. As the awareness of its benefits in microsurgery and implant dentistry continues to grow, the market for fibrin sealant is expected to thrive. Manufacturers and suppliers in this market must remain at the forefront of technology and innovation to meet the evolving demands of surgeons and healthcare professionals, ensuring continued growth and improved surgical outcomes worldwide.

Rising Demand for Dental Surgeries Drives the Demand for Fibrin Sealant Market

The global fibrin sealant market is experiencing significant growth, primarily driven by the rising demand for dental surgeries.  Dental conditions such as periodontal disease, tooth decay, and oral infections continue to be common health issues worldwide. These conditions often necessitate various dental surgical procedures for diagnosis and treatment. The demand for dental surgeries is on the rise due to factors such as an aging population, increased awareness of oral health, and advances in dental technology. These surgeries encompass a wide range of procedures, including tooth extractions, dental implant placements, gum surgeries, and root canal treatments. Fibrin sealant, also known as tissue glue, plays a pivotal role in dental surgery. It is used to control bleeding, facilitate tissue closure, and promote efficient wound healing. The growth of the global dental market and the UK dental practices industry further supports the expanding demand for fibrin sealants. Valued at USD 35.40 billion in 2023, the global dental market is projected to reach USD 95.37 billion by 2032, driven by increasing dental procedures and cosmetic dentistry. Meanwhile, the UK dental practices industry is valued at approximately USD 9.5 billion in 2024 (converted from £7.7 billion), highlighting strong demand for advanced surgical and wound management solutions. Fibrin sealants play a crucial role in dental surgeries by promoting hemostasis and enhancing post-operative healing. As dental procedures become more complex and frequent, the need for effective wound closure products like fibrin sealants is rising. This robust growth in the dental market reinforces the positive outlook for fibrin sealant adoption in oral and maxillofacial applications globally.

In dental surgeries, the use of fibrin sealant offers several advantages. It ensures hemostasis (control of bleeding), reduces the risk of infection, and accelerates the healing process. Fibrin sealant also provides a reliable tissue seal, which is crucial in preventing complications. The success of dental surgical procedures heavily relies on the precision and effectiveness of tissue closure. Dental practitioners seek reliable and biocompatible adhesives that can securely close tissues, minimizing postoperative complications. Fibrin sealant is a versatile adhesive used in various dental specialties, including oral and maxillofacial surgery, periodontics, endodontics, and implant dentistry. Its applicability across different dental procedures makes it an essential tool in dental practice. The growing demand for precise and efficient tissue adhesives in dental surgeries is driving the need for specialized fibrin sealant products. Dental professionals and surgeons are seeking advanced solutions to optimize surgical outcomes.

Biomaterial Alternative for Periodontal Surgery that Accelerates Periodontal Wound Healing and Regeneration

The global fibrin sealant market is experiencing significant growth, driven by the increasing demand for biomaterial alternatives in periodontal surgery that accelerate periodontal wound healing and regeneration. Periodontal disease, a common dental ailment, can lead to severe gum and bone damage if left untreated. Periodontal surgical interventions are often necessary to restore oral health. Periodontal surgeries are complex and require precise wound closure and tissue regeneration. Effective biomaterials are needed to enhance the outcomes of these surgeries. Fibrin sealant, a biocompatible adhesive derived from human plasma proteins, is increasingly being utilized as a biomaterial alternative in periodontal surgery. It offers unique advantages in promoting tissue regeneration and accelerating wound healing. Fibrin sealant serves as a scaffold that supports tissue growth and healing. It provides a stable framework for cell migration and proliferation while securing wound closure.

In periodontal surgery, the use of fibrin sealant offers several benefits. It aids in hemostasis, prevents infection, and accelerates tissue repair. Fibrin sealant also contributes to bone regeneration and minimizes postoperative complications. Patients and dental professionals alike seek biomaterials that can enhance periodontal wound healing, reduce recovery time, and improve overall oral health. Fibrin sealant is versatile and can be used in various periodontal procedures, including gingival grafts, bone grafts, and guided tissue regeneration. Its applicability across different periodontal surgeries makes it a valuable asset in periodontal practice.

Download Free Sample Report

Key Market Challenges

High Cost of Fibrin Sealants

The high cost of fibrin sealants represents a substantial obstacle to the growth of the global Fibrin Sealant market. Fibrin sealants are biologically derived adhesives used in surgical procedures to facilitate hemostasis, tissue sealing, and wound closure. Their effectiveness and safety have made them invaluable in various surgical applications, including cardiovascular, orthopedic, and general surgery. However, the production and processing of fibrin sealants involves complex biotechnological processes and stringent quality control, resulting in elevated production costs.

The high cost of fibrin sealants can strain healthcare budgets, deter some healthcare facilities from adopting these products, and limit market growth potential. Additionally, affordability concerns can lead to a preference for alternative hemostatic and tissue sealing solutions, further hampering market expansion.

To address this challenge and stimulate growth in the Fibrin Sealant market, manufacturers must explore strategies to optimize production processes, improve cost-efficiency, and collaborate with healthcare providers to showcase the long-term benefits and cost-effectiveness of fibrin sealant use. By making these vital surgical aids more accessible, the market can continue to advance in the field of medical procedures and surgical interventions.

Risk of Transmission

The risk of disease transmission poses a significant obstacle to the growth of the global Fibrin Sealant market. Fibrin sealants are crucial in surgical procedures, offering effective hemostasis and tissue sealing. However, many fibrin sealant products are derived from human or animal plasma, which raises concerns about the potential transmission of infectious diseases.

In healthcare environments, ensuring patient safety is paramount, and the risk of disease transmission is a significant concern. Even with rigorous screening and processing procedures, there remains a small but inherent risk associated with plasma-derived fibrin sealants.

To address this challenge and foster market growth, manufacturers are increasingly focusing on developing safer, recombinant or synthetic fibrin sealant alternatives. These alternatives eliminate the risk of disease transmission and are gaining acceptance in surgical settings. Regulatory agencies are also continually updating safety standards to minimize these risks.

By actively promoting and adopting these safer fibrin sealant solutions, the market can mitigate concerns related to disease transmission and ensure that these vital surgical tools continue to drive advancements in healthcare and surgical procedures.

Key Market Trends

Government Funding and Improvement in the Quality of Healthcare

Advancements in bonding technologies are a fundamental trend driving the growth of the global Fibrin Sealant market. As industries continue to evolve, there is a growing demand for Fibrin Sealant that offer improved bonding capabilities, versatility, and efficiency. These advancements are not only transforming traditional bonding processes but also expanding the applications of Fibrin Sealant across various sectors.

The development of innovative bonding technologies includes the formulation of adhesive products with enhanced chemical compositions, allowing them to bond a wider range of plastic substrates effectively. Additionally, improvements in curing mechanisms, such as UV curing and cyanoacrylate technology, have accelerated bonding speeds and enhanced the overall performance of Fibrin Sealant.

These advancements are particularly crucial in industries like automotive, electronics, and medical devices, where plastic components play a significant role. As manufacturers seek reliable, high-performance bonding solutions to improve product quality and assembly efficiency, the global Fibrin Sealant market is poised for substantial growth. Companies that invest in cutting-edge bonding technologies and adapt to evolving industry demands are well-positioned to capitalize on this transformative trend.

Advancements in Technology to Meet Increasing Surgical Procedures

Advancements in technology to meet the surging demand for surgical procedures represent a crucial trend propelling the growth of the Global Fibrin Sealant Market. The modern healthcare landscape is witnessing an unprecedented rise in surgical interventions, driven by factors such as an aging population, increased prevalence of chronic diseases, and expanding access to healthcare services.

Fibrin sealants, with their remarkable ability to promote hemostasis and tissue sealing, have become indispensable tools in surgical settings. To keep pace with the growing number and complexity of surgeries, technological advancements in fibrin sealant formulations and delivery methods are paramount. These innovations focus on improving the efficacy, precision, and convenience of fibrin sealant application, ultimately enhancing patient outcomes.

Novel technologies include the development of ready-to-use fibrin sealant sprays, advanced applicators, and formulations that enable quicker and more efficient hemostasis and tissue bonding. As surgical procedures continue to rise, the Global Fibrin Sealant Market is set to expand further, with technology-driven solutions addressing the evolving needs of surgeons and healthcare providers.

Segmental Insights

End User Insights

The hospital segments are projected to experience rapid growth during the forecast period. driven by the increasing number of CABG (coronary artery bypass grafting) and other cardiovascular surgeries conducted in hospital settings. Notably, research by the Agency for Healthcare Research and Quality reveals a substantial 20.0% increase in percutaneous transluminal coronary angioplasty procedures within U.S. hospitals between 2001 and 2011. This surge in surgical procedures performed within hospital premises contributes to the segment's growth. Simultaneously, there is a gradual shift in patient preferences from inpatient visits to outpatient visits, creating substantial growth opportunities for the specialty clinics end-user segment from 2019 to 2026. This shift underscores the increasing importance of specialized healthcare facilities.

Download Free Sample Report

Regional Insights

The Asia-Pacific region was poised to be largest market during the forecast period. The Asia-Pacific region is expected to experience robust growth, attributed to the entry of new market players and the implementation of strategic marketing policies. Additionally, the rapid development of healthcare infrastructure in countries like China and India, combined with increased healthcare expenditure in Japan and Australia, presents significant growth opportunities in this region by 2030.

Recent Developments

• In February 2024, Principal Technologies acquired Vivostat, a Danish company specializing in autologous fibrin sealant technology, through a Share Purchase Agreement finalized on February 6. The deal involved the acquisition of 100% of Vivostat's equity and marks a strategic effort to strengthen Principal Technologies’ presence in the global fibrin sealants market, particularly across the EMEA region. Vivostat’s innovative technology, used in over 200,000 surgical procedures, offers advanced, patient-specific wound sealing solutions. This acquisition not only broadens Principal Technologies’ product portfolio but also reflects the growing demand for effective and safe fibrin sealant applications in modern surgical and wound care practices.
• In July 2024, Corza Medical finalized the acquisition of Takeda's TachoSil manufacturing facility in Linz, Austria, with the deal completed on July 1. This follows Corza Medical’s earlier acquisition of TachoSil’s commercial rights in January 2021. By gaining full control of the manufacturing process, Corza aims to enhance supply chain efficiency and provide improved service and support to its global customer base. TachoSil, a fibrin sealant patch widely used to control bleeding during surgeries, strengthens Corza Medical’s position in the fibrin sealants market and reinforces its commitment to delivering high-quality surgical hemostatic solutions worldwide.
• In 2024, Takeda Pharmaceutical Company completed a strategic merger with BioSeal Technologies, a specialist in fibrin sealant and hemostatic technologies. Structured as a short-form merger with a wholly owned subsidiary, the transaction involved no changes to Takeda’s name, address, operations, or capital structure. This move is intended to enhance Takeda’s position in the global hemostatic market by integrating BioSeal’s technical expertise in surgical bleeding control. While the financial impact on Takeda’s consolidated earnings is expected to be minimal, the merger aligns with the company’s broader strategy to strengthen its surgical care portfolio and expand its advanced wound management solutions.
• In November 2023, Ethicon, a Johnson & Johnson MedTech company, introduced ETHIZIA, a synthetic hemostatic sealing patch clinically proven to achieve rapid and sustained bleeding control. Designed for both open and minimally invasive surgeries, ETHIZIA demonstrated 82% effectiveness in stopping bleeding within 30 seconds, six times faster than the leading fibrin sealant patch. This innovation follows Ethicon’s 2022 acquisition of GATT Technologies, a Netherlands-based firm specializing in synthetic hemostatic solutions. With CE Mark approval and global rollout planned, ETHIZIA enhances Ethicon’s biosurgery portfolio, strengthening its position in the competitive fibrin sealants and hemostasis solutions market.
• In 2018, Baxter introduced new Tisseel prima syringe at 2018 American Association of Gynecologic Laparoscopists meeting. Baxter also unveiled its new Tisseel 40cm Duplotip Rigid Applicator, an extended length applicator that is helpful when surgeons need to apply Tisseel to hard-to-reach areas laparoscopically.
• In 2018, Baxter International acquired CryoLife, a leading provider of cryopreserved human allografts and biomaterials, for $3.1 billion. This acquisition gave Baxter access to CryoLife's fibrin sealant product, FloSeal.

Key Market Players

• Johnson and Johnson
• Baxter International Inc.
• Nordson Corporation (Nordson Medical)
• Corza Health Inc
• Becton Dickinson and Company
• CSL Behring LLC
• Grifols SA
• Shanghai RAAS Blood Products Co., Ltd.
• Vivostat A/S
• Hemarus Therapeutics Ltd

In this report, the Global Fibrin Sealant Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Fibrin Sealant Market, By Type:

o   Liquid Form

o   Patch

• Fibrin Sealant Market, By End User:

o   Ambulatory Surgical Centers

o   Hospitals

o   Specialty Clinics

• Fibrin Sealant Market, By Region:

o   Asia-Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

§  Kuwait

§  Turkiye

§  Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Fibrin Sealant Market.

Available Customizations:

Global Fibrin Sealant market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Fibrin Sealant Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]